Menatetrenone ameliorates osteopenia in disuse-affected limbs of vitamin D- and K-deficient stroke patients.

Abstract

Significant reduction in bone mineral density (BMD) occurs in stroke patients on the hemiplegic and contralateral sides, correlating with the degree of paralysis and vitamin D and K deficiency due to malnutrition, and increasing the risk of hip fracture. We evaluated the efficacy of vitamin K2 (menatetrenone: menaquinone-4; MK-4) in maintaining BMD by comparing serum biochemical indices of bone metabolism between treated and untreated patients. In a random and prospective study, of 108 hemiplegic patients following stroke, 54 received 45 mg menatetrenone daily (MK-4 group, n = 54) for 12 months, and the remaining 54 (untreatment group) did not. Nine patients excluded from the study. The BMD in the second metacarpals and serum indices of bone metabolism were determined. BMD on the hemiplegic side increased by 4.3% in the MK-4 group and decreased by 4.7% in the untreated group (p < 0.0001), while BMD on the intact side decreased by 0.9% in the MK-4 group and by 2.7% in the untreated group (p < 0.0001). At baseline, patients of both groups showed vitamin D and K1 deficiencies, high serum levels of ionized calcium, pyridinoline cross-linked carboxyterminal telopeptide of type I collagen (ICTP), and low levels of parathyroid hormones (PTH) and bone Gla proteins (BGP), indicating that immobilization-induced hypercalcemia inhibits renal synthesis of 1, 25-dihydroxyvitamin D (1, 25-[OH]2D) and compensatory PTH secretion. Both vitamins K1 and K2 increased by 97.6% and 666.9%, respectively, in the MK-4 group. Correspondingly, a significant increase in BGP and decreases in both ICTP and calcium were observed in the MK-4 group, in association with a simultaneous increase in both PTH and 1, 25-[OH]2D. One patient in the untreated group suffered from a hip fracture, compared with none in the MK-4 group. The treatment with MK-4 can increase the BMD of disused and vitamin D- and K-deficient hemiplegic bone by increasing the vitamin K concentration, and it also can decrease calcium levels through inhibition of bone resorption, resulting in an increase in 1, 25-[OH]2D concentration.

• Authors: Y Sato, Y Honda, H Kuno, K Oizumi
• Journal: Bone (Bone) Vol. 23 Issue 3 Pg. 291-6 (Sep 1998) ISSN: 8756-3282 [Print] United States
• PMID: 9737352 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Biomarkers
• Hemostatics
• Vitamin K 2
• Vitamin K
• menatetrenone
• Vitamin K 1
• menaquinone 7

Topics

• Aged
• Biomarkers (blood)
• Bone Density (drug effects)
• Bone Diseases, Metabolic (blood, complications, drug therapy)
• Cerebrovascular Disorders (complications)
• Female
• Hemiplegia (blood, etiology)
• Hemostatics (administration & dosage, therapeutic use)
• Humans
• Male
• Metacarpus (drug effects)
• Middle Aged
• Prospective Studies
• Vitamin D Deficiency (complications)
• Vitamin K (administration & dosage, analogs & derivatives, blood, therapeutic use)
• Vitamin K 1 (blood)
• Vitamin K 2 (analogs & derivatives)
• Vitamin K Deficiency (complications)